hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06269757 id: 23-01514 briefTitle: Exercise Program for ITB Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-08-01 date: 2026-04-01 date: 2024-02-21 date: 2024-02-21 name: NYU Langone Health class: OTHER briefSummary: Patients with diagnosed iliotibial band (ITB) syndrome indicated for non-operative management will be randomized to individualized exercise program or standard physical therapy over the course of 3 months to determine any possible difference in clinical outcomes. conditions: Iliotibial Band Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Individualized Exercise Program name: Standard Physical Therapy measure: Knee injury and Osteoarthritis Outcome Score Physical Short-Form (KOOS-PS) Score measure: Visual Analogue Scale (VAS) Score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269744 id: 23-01032 briefTitle: Proactive Outreach With FIT acronym: PROOF overallStatus: ENROLLING_BY_INVITATION date: 2024-03-13 date: 2025-07-31 date: 2026-04-30 date: 2024-02-21 date: 2024-03-29 name: NYU Langone Health class: OTHER briefSummary: The purpose of the study is to boost colorectal cancer (CRC) screening rates in an underserved population in Brooklyn through organized, proactive outreach of mailed Fecal Immunochemical Tests (FIT), utilizing evidence-based interventions tailored to the needs of the population. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 3000 type: ESTIMATED name: Proactive Screening Outreach measure: Proportion of Participants who Complete FIT Test by Month 6 measure: Proportion of Participants with Positive FIT who Complete Colonoscopy by Month 6 sex: ALL minimumAge: 45 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: Brooklyn state: New York zip: 11203 country: United States lat: 40.6501 lon: -73.94958 facility: Community Health Care Network of New York city: Brooklyn state: New York zip: 11206 country: United States lat: 40.6501 lon: -73.94958 hasResults: False
nctId: NCT06269731 id: Thyroid cancer briefTitle: Anxiety & Depression in Thyroid Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-12 date: 2026-03 date: 2024-02-21 date: 2024-02-21 name: Assiut University class: OTHER briefSummary: 1. To identify the prevalence of both anxiety and depression in thyroid cancer patients
2. To assess quality of life in thyroid cancer patients conditions: Thyroid Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 159 type: ESTIMATED name: Hamilton depression Rating Scale measure: the prevalence of anxiety in thyroid cancer patients measure: the prevalence of depression in thyroid cancer patients measure: assess quality of life in thyroid cancer patients sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269718 id: CMRPG8N0471 briefTitle: The Changes of Masticatory / Swallowing Functions and Oropharyngeal Muscle Mass on Sonography After Comprehensive Swallowing Training and Tongue - Pressure Resistance Training in Stroke Patients With Dysphagia overallStatus: RECRUITING date: 2023-12-01 date: 2024-07-31 date: 2024-07-31 date: 2024-02-21 date: 2024-02-21 name: Chang Gung Memorial Hospital class: OTHER briefSummary: The aims of this study are:
3. To explore the correlation between clinical mastication and swallowing functions, tongue pressure, oropharyngeal muscle thickness and ultrasound imaging results in patients with dysphagia and stroke. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: swallowing therapy name: IOPI therapy measure: the change from baseline to time of swallowing muscle strength measure: the change from baseline to time of Masster thickness measure: the change from baseline to time of tongue muscles thickness measure: the change from baseline to time of general muscle mass measure: Measure the change in grip strength (by Jamar hand dynamometer) measure: the change from baseline to time of swallowing functions measure: the change from baseline to time of clinical nutrition status measure: the change from baseline to time of swallowing functions 100 ml water test measure: the change from baseline to time of quality of life sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ChangGungMH status: RECRUITING city: Kaohsiung zip: 833 country: Taiwan name: Yuchi Huang, MD role: CONTACT phone: 886-7-7317123 phoneExt: 6286 email: hyuchi@gmail.com lat: 22.61626 lon: 120.31333 hasResults: False
nctId: NCT06269705 id: 006-C-301 briefTitle: ZILRETTA in Subjects With Glenohumeral Osteoarthritis overallStatus: RECRUITING date: 2024-02-05 date: 2025-08 date: 2025-08 date: 2024-02-21 date: 2024-04-03 name: Pacira Pharmaceuticals, Inc class: INDUSTRY briefSummary: Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo
* To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo and TCA-IR conditions: Glenohumeral Osteoarthritis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Only unblinded team (pharmacist, unblinded coordinator, drug administrator) will know the treatment assignment. A site-specific blinding plan will be developed to ensure blinding. Unblinded team will only interact with the subject at treatment and will not have any blinded roles on the study (only exception- informed consent). The subject and the assessor responsible for assessments/safety monitoring will be blinded. Site and Sponsor personnel/representatives will be blinded, with the following Sponsor/representative exceptions: unblinded monitors for performing drug accountability, unblinded clinical manager for reviewing unblinded monitoring visit reports and escalation of site unblinded issues, inventory manager for addressing product-related issues, and regulatory personnel for safety reporting. Information regarding treatment assignments will be kept securely at Sponsor. whoMasked: INVESTIGATOR count: 250 type: ESTIMATED name: ZILRETTA name: TCA-IR name: Placebo measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 12 for ZILRETTA relative to placebo measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 12 for ZILRETTA relative to TCA-IR measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 18 for ZILRETTA relative to TCA-IR measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 2 for ZILRETTA relative to placebo measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 4 for ZILRETTA relative to placebo measure: Change from Baseline on the Worst Daily Pain (24-hr) mean score at Week 8 for ZILRETTA relative to placebo measure: Change from Baseline at Week 12 on the SPADI total score and subscales for ZILRETTA relative to placebo measure: Change from Baseline at Week 12 on the SPADI total score and subscales for ZILRETTA relative to TCA-IR sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alabama Orthopaedic Center- Research status: RECRUITING city: Birmingham state: Alabama zip: 35243 country: United States name: Robert Sorrell, MD role: CONTACT lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06269692 id: 2023-A01353-42 briefTitle: MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators acronym: SMART-DEF overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2030-04-01 date: 2030-04-01 date: 2024-02-21 date: 2024-02-21 name: Central Hospital, Nancy, France class: OTHER briefSummary: Implantable cardioverter-defibrillators (ICD) are currently recommended for the primary prevention of sudden cardiac death (SCD) in patients with a remote (\>6 weeks) myocardial infarction (MI) and a low (≤35%) left ventricular ejection fraction (LVEF).
Ventricular tachycardia (VT) and/or ventricular fibrillation (VF), which are responsible for most SCDs, result from the presence of surviving myocytes embedded within fibrotic MI-scar. The presence of these surviving myocytes, as well as their specific arrhythmic characteristics, is not captured by LVEF. Hence, the use of LVEF as a unique risk-stratifier of SCD results in a low proportion (17 to 31%) of appropriate ICD device therapy at 2 years. Consequently, most patients with a prophylactic ICD do not present VT/VF requiring ICD therapy prior to their first-ICD battery depletion. Thus, many patients are exposed to ICD complications, such as inappropriate shocks, without deriving any health benefit. Therefore, the current implantation strategy of prophylactic ICDs, based on LVEF only, needs to be improved in post-MI patients. conditions: Myocardial Infarction conditions: Ventricular Tachycardia conditions: Ventricular Fibrillation conditions: Sudden Cardiac Death studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 1812 type: ESTIMATED name: MRI screening name: Implantable Loop Recorder name: Implantable Cardioverter Defibrillator measure: Occurrence of Sudden Cardiac Death (SCD) during the follow-up period measure: Total number of deaths during the follow-up period measure: Total number of deaths from cardiovascular cause during the follow-up period measure: Total number of SCD due to ventricular arrhythmia during the follow-up period measure: Total number (per patient) of sustained VT episodes treated by the ICD or recorded by the ILR during the follow-up period measure: Total number (per patient) of VF episodes treated by the ICD or recorded by the ILR during the follow-up period measure: Total number of hospitalizations due to cardiovascular causes during the follow-up period measure: Duration of hospitalizations due to cardiovascular causes during the follow-up period measure: Total number of hospitalizations from any cause during the follow-up period measure: Duration of hospitalizations from any cause during the follow-up period measure: Quality of life assessed by the scoring obtained from EuroQol questionnaires (EQ-5D-5L) during the follow-up period measure: Measurements of the estimated costs measure: Dice scores of the segmentation of the left ventricle and scar obtained from new MR sequences measure: Contour distance metrics of the segmentation of the left ventricle and scar obtained from new MR sequences measure: Dice scores of the accuracy of fully automated segmentation of the left ventricle and scar measure: Contour distance metrics of the accuracy of fully automated segmentation of the left ventricle and scar sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRU Nancy city: Vandœuvre-lès-Nancy zip: 54511 country: France name: Christian de CHILLOU, MD, PhD role: CONTACT email: c.dechillou@chru-nancy.fr name: Guillaume DROUOT, PhD role: CONTACT email: g.drouot@chru-nancy.fr lat: 48.65 lon: 6.18333 hasResults: False
nctId: NCT06269679 id: RC23_0336 briefTitle: CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis. acronym: 3D STARS overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-05-01 date: 2028-05-01 date: 2024-02-21 date: 2024-02-21 name: Nantes University Hospital class: OTHER briefSummary: 1. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination/Orthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination/CBCT approach on the oral health status in IE patients.
Thus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination/CBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes. conditions: Infective Endocarditis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 170 type: ESTIMATED name: CBCT measure: Superiority of CBCT measure: Superiority of CBCT measure: Superiority of CBCT measure: Diagnostic at inclusion measure: Incident symptomatic OIF measure: Incident asymptomatic OIF measure: Oral hygiene measure: Follow-up habits measure: Follow-up habits measure: Oral health quality of life measure: Premature end of study sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Bordeaux - Site Pellegrin city: Bordeaux country: France name: Elise ARRIVE role: CONTACT phone: +33/5 56 79 56 79 email: elise.arrive@u-bordeaux.fr lat: 44.84044 lon: -0.5805 facility: CHU Grenoble city: Grenoble country: France name: Cécile CHATEL role: CONTACT phone: +33/4 76 76 50 26 email: cchatel1@chu-grenoble.fr lat: 45.16667 lon: 5.71667 facility: CHRU Nancy city: Nancy country: France name: Vanessa MOBY role: CONTACT phone: +33/3 83 39 18 00 email: vanessa.moby@univ-lorraine.fr lat: 48.68439 lon: 6.18496 facility: CHU Nantes city: Nantes country: France name: Philippe LESCLOUS role: CONTACT phone: +33/2.40.41.29.40 email: philippe.lesclous@chu-nantes.fr name: Astrid GARREAU role: CONTACT email: astrid.garreau@chu-nantes.fr lat: 47.21725 lon: -1.55336 facility: AP-HP - Site Bretonneau city: Paris country: France name: MESSECA Clément role: CONTACT phone: +33/1 53 11 18 00 email: clement.messeca@aphp.fr lat: 48.85341 lon: 2.3488 facility: CHU Toulouse city: Toulouse country: France name: Sarah COUSTY role: CONTACT phone: +33/5.61.32.20.30 email: cousty.s@chu-toulouse.fr lat: 43.60426 lon: 1.44367 facility: CHRU Tours city: Tours country: France name: Frédéric DENIS role: CONTACT phone: +33/2 47 47 47 47 email: frederic.denis@univ-tours.fr lat: 47.38333 lon: 0.68333 hasResults: False
nctId: NCT06269666 id: OPT1100 briefTitle: P200TxE Diseased Eye Image Collection overallStatus: RECRUITING date: 2024-01-31 date: 2024-06-30 date: 2024-06-30 date: 2024-02-21 date: 2024-02-21 name: Optos, PLC class: INDUSTRY briefSummary: The primary objective is to collect images on the P200TxE device in diseased eyes. conditions: Retinal Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: P200TxE measure: Number of images sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bennett and Bloom Eye Centers status: RECRUITING city: Louisville state: Kentucky zip: 40215 country: United States name: Megan Kingdon role: CONTACT phone: 513-305-8654 email: megankingdon@eyecare-partners.com lat: 38.25424 lon: -85.75941 hasResults: False
nctId: NCT06269653 id: 10001944 id: 001944-AG briefTitle: Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide overallStatus: RECRUITING date: 2024-05-01 date: 2026-03-01 date: 2026-03-01 date: 2024-02-21 date: 2024-04-26 name: National Institute on Aging (NIA) class: NIH briefSummary: Background:
D3-Creatine: Participants will take 1 pill of D3-Creatine, which occurs naturally in muscle. conditions: Healthy Volunteers studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 75 type: ESTIMATED measure: Measure the turnover proteins in humans across tissues, age, and sex. measure: Test the hypothesis that older age is associated with diminished protein turnover. sex: ALL minimumAge: 20 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of Aging, Clinical Research Unit status: RECRUITING city: Baltimore state: Maryland zip: 21224 country: United States name: Luigi Ferrucci, M.D. role: CONTACT phone: 410-558-8110 email: ferruccilu@grc.nia.nih.gov lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06269640 id: 10001640 id: 001640-H briefTitle: NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-10-01 date: 2027-10-01 date: 2024-02-21 date: 2024-04-26 name: National Heart, Lung, and Blood Institute (NHLBI) class: NIH briefSummary: Background:
Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO.
Participants will have 3 follow-up visits within 1 year. conditions: Hypertrophic Cardiomyopathy conditions: Left Ventricular Septal Hypertrophy conditions: Mitral Valve Disease conditions: Aortic Valve Stenosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Septal Scoring Along Midline Endocardium measure: Technical success measure: Safety measure: Complete heart block requiring permanent pacemaker sex: ALL minimumAge: 21 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Emory University Hospital city: Atlanta state: Georgia zip: 30322 country: United States name: Robert Lederman, M.D. role: CONTACT phone: 301-402-6769 email: lederman@nih.gov lat: 33.749 lon: -84.38798 hasResults: False
nctId: NCT06269627 id: 10001644 id: 001644-AA briefTitle: Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-02-21 date: 2024-04-26 name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) class: NIH briefSummary: Background:
Participants will have a procedure called electroencephalography (EEG): A gel will be applied to certain locations on their scalp, and a snug cap will be placed on their head. The cap has sensors with wires. The sensors detect electrical activity in the brain. Participants will lie still and perform 2 tasks: they will look at different shapes and press a button when they see a specific one; and they will listen to tones and press dedicated buttons when they hear the corresponding tones.
Participants may have up to three follow-up visits for 6 months. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: Acamprosate calcium name: Placebo measure: Reduction of beta power measure: Promotion of alpha power in active group compared to placebo group. measure: No change in slow band (delta and theta) power in active group compared to placebo group. measure: Reduction of theta event-related synchronization in active group compared to placebo group. measure: Amplification and hastening of P300 in active group compared to placebo group. measure: Correlation of EEG markers of acamprosate treatment with clinical measures of anxiety and alcohol craving measure: Correlation of EEG markers of acamprosate treatment with polysomnography markers measure: Correlation of polysomnography markers of acamprosate treatment with clinical measures of anxiety and alcohol craving sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center city: Bethesda state: Maryland zip: 20892 country: United States name: NIH Clinical Center Office of Patient Recruitment (OPR) role: CONTACT phone: 800-411-1222 phoneExt: TTY dial 711 email: ccopr@nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06269614 id: QOL334829 briefTitle: Assessing the Gut Microbiome and Its Association With Pediatric Stress and Cognition overallStatus: RECRUITING date: 2023-01-12 date: 2025-12-31 date: 2025-12-31 date: 2024-02-21 date: 2024-02-21 name: Nova Southeastern University class: OTHER briefSummary: Using a metabolomics approach in combination with eye-tracking data, this research study proposes to gather evidence from two interrelated body systems (gut and brain) in order to assess how the microbiome is involved in stress modulated symptoms in children with autism and children exposed to repeated stress in comparison to a control group. conditions: Autism Spectrum Disorder conditions: Adverse Childhood Experiences conditions: Stress Reaction studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 75 type: ESTIMATED name: Probiotic measure: Enteric Microbiome abundance measure: Enteric Microbiome diversity measure: Improved response to stressor measure: Improved physiological response to stressor sex: ALL minimumAge: 4 Years maximumAge: 95 Months stdAges: CHILD facility: Nova Southeastern University College of Nursing status: RECRUITING city: Davie state: Florida zip: 33314 country: United States name: Gesulla Cavanaugh, PhD role: CONTACT phone: 954-262-1980 email: gcavanaugh@nova.edu lat: 26.06287 lon: -80.2331 hasResults: False
nctId: NCT06269601 id: HÜ- FTR- BD- 02 briefTitle: The Reliability of the Upper Limb Rotation Test in Adolescent Male Basketball Players overallStatus: COMPLETED date: 2023-08-10 date: 2023-09-15 date: 2023-09-15 date: 2024-02-21 date: 2024-02-28 name: Hacettepe University class: OTHER briefSummary: The objective of the study is to examine the reliability of the Upper Limb Rotation Test in adolescent male basketball players aged between 14 and 16. According to the sample size calculation for the study, 51 athletes were included. The Upper Limb Rotation Test was administered to the athletes twice, with a one-week interval. The athlete was positioned in a plank stance with shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus making contact with the wall. The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated. The Upper Extremity Rotation Test is a reliable assessment tool for evaluating performance in adolescent basketball players aged 14-16, particularly in relation to shooting skills. conditions: Sports Physical Therapy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 14-18 years basketball players primaryPurpose: OTHER masking: NONE count: 51 type: ACTUAL name: Upper Limb Rotation Test measure: The Reliability of the Upper Limb Rotation Test sex: MALE minimumAge: 14 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Hacettepe University city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False